Influence of anxiety on health outcomes in COPD

Thorax

Volumn 65, Issue 3, 2010, Pages 229-234

  Eisner, Mark D ^a   Blanc, Paul D ^a   Yelin, Edward H ^a   Katz, Patricia P ^a   Sanchez, Gabriela ^b   Iribarren, Carlos ^b   Omachi, Theodore A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGITATION; ANXIETY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISABILITY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EMOTION; EXERCISE; FEAR; FEMALE; FUNCTIONAL DISEASE; HEALTH CARE DELIVERY; HEALTH STATUS; HEART PALPITATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MULTIVARIATE ANALYSIS; MUSCLE TONE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RISK ASSESSMENT; SCREENING; SHORT FORM 12; SHORT FORM 36; SPIROMETRY; SWEATING;

EID: 77949811769     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.126201     Document Type: Article

References (47)

1. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
2. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
3. Singh D, Brooks J, Hagan G, et al. Superiority of "triple" therapy with salmeterol/ fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-8.
4. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
5. Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med 2008;121:789-96.
6. Omachi TA, Katz PP, Yelin EH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med 2009;122:778.e9-15.
7. Hill K, Geist R, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Respir J 2008;31:667-77.
8. Goodwin RD, Zvolensky MJ, Keyes KM. Nicotine dependence and mental disorders among adults in the USA: evaluating the role of the mode of administration. Psychol Med 2008;38:1277-86.
9. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134(4 Suppl):43S-56S.
10. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008;178:913-20.
11. Eisner MD, Iribarren C, Yelin EH, et al. Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease. Am J Epidemiol 2008;167:1090-101.
12. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009;64:6-12.
13. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-75.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM IV. Arlington, VA: American Psychiatric Publishing, 1994.
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
16. Mykletun A, Stordal E, Dahl AA. Hospital Anxiety and Depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 2001;179:540-4.
17. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77.
18. Funk GC, Kirchheiner K, Burghuber OC, et al. BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD: a cross-sectional study. Respir Res 2009;10:1.
19. Puhan MA, Frey M, Buchi S, et al. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2008;6:46.
20. Eisner MD, Trupin L, Katz PP, et al. Development and validation of a survey-based COPD severity score. Chest 2005;127:1890-7.
21. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
22. Hajiro T, Nishimura K, Tsukino M, et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1185-9.
23. Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008;178:491-9.
24. Ong KC, Lu SJ, Soh CS. Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Int J Chron Obstruct Pulmon Dis 2006;1:91-6.
25. Eisner MD, Iribarren C, Yelin E. The BODE index and COPD severity score offer complementary assessment of COPD status. Am J Respir Crit Care Med 2008;177:A399.
26. American Thoracic Society. Standardization of spirometrye-1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285-98.
27. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
28. Walters JA, Wood-Baker R, Walls J, et al. Stability of the EasyOne ultrasonic spirometer for use in general practice. Respirology 2006;11:306-10.
29. Perez-Padilla R, Vazquez-Garcia JC, Marquez MN, et al. The long-term stability of portable spirometers used in a multinational study of the prevalence of chronic obstructive pulmonary disease. Respir Care 2006;51:1167-71.
30. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50.
31. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
32. Hajiro T, Nishimura K, Jones PW, et al. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1874-8.
33. Chen H, Eisner MD, Katz PP, et al. Measuring disease-specific quality of life in obstructive airway disease: validation of a modified version of the airways questionnaire 20. Chest 2006;129:1644-52.
34. Alemayehu B, Aubert RE, Feifer RA, et al. Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease. Value Health 2002;5:436-41.
35. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
36. Sciurba F, Criner GJ, Lee SM, et al. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003;167:1522-7.
37. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
38. Sternfeld B, Ngo L, Satariano WA, et al. Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. Am J Epidemiol 2002;156:110- 21.
39. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults - United States, 1997. MMWR Morb Mortal Wkly Rep 1999;48:993-6.
40. Anon. National Center for Health Statistics. National Health Interview Survey.
41. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
42. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
43. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven Publishers, 1998.
44. Putman-Casdorph H, McCrone S. Chronic obstructive pulmonary disease, anxiety, and depression: state of the science. Heart Lung 2009;38:34-47.
45. Gudmundsson G, Gislason T, Janson C, et al. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med 2006;100:87-93.
46. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005;26:414-9.
47. Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000;41:465-71.